We have designed and optimized a series of ADCs that deliver TLR7/8 agonists to lymphocytes.  We will describe the preparation and characterization of these ADCs, along with data that demonstrates that they selectively activate lymphocytes in an antigen-dependent manner.  Further, we will describe preliminary data to show that these ADCs can be delivered to tumor tissue and activate nearby tumor-associated-macrophages.  Unlike traditional cytotoxic ADCs, these agents are non-toxic and are anticipated to locally stimulate an immune response the results in tumor ablation.

Targeted delivery of TLR7/8 agonists using ADC technology

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.